2. Immunology/Inflammation
  3. Transmembrane Glycoprotein
  4. PHST001

PHST001 is a humanized anti-CD24 antibody. PHST001 binds cell-surface CD24, blocks CD24-Siglec10 interaction, and engages Fc receptors to promote macrophage-mediated tumor cell phagocytosis. PHST001 inhibits growth of breast cancer and ovarian cancer, and reduces metastatic lesions in mouse xenograft models. PHST001 can be used for the research of triple negative breast cancer, HER2+ breast cancer, metastatic tumors, and ovarian cancer.

For research use only. We do not sell to patients.

PHST001

PHST001 Chemical Structure

Size Stock
1 mg   Get quote  
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

PHST001 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

PHST001 is a humanized anti-CD24 antibody. PHST001 binds cell-surface CD24, blocks CD24-Siglec10 interaction, and engages Fc receptors to promote macrophage-mediated tumor cell phagocytosis. PHST001 inhibits growth of breast cancer and ovarian cancer, and reduces metastatic lesions in mouse xenograft models. PHST001 can be used for the research of triple negative breast cancer, HER2+ breast cancer, metastatic tumors, and ovarian cancer[1][2][3].

Species Reactivity

Human
In Vitro

PHST001 binds specifically and with high affinity to human CD24 peptide, with no cross-reactivity to CD24 peptides from other tested species or a randomized control peptide[1].
PHST001 binds with high affinity to CD24 on the surface of multiple human cancer cell lines, including BT474, MFM223, SKBR3, OVCAR3, SKOV3, NCI-H292, NCI-H1563, BXPC3, PACADD-137, HT29, and DLD1 cell lines[1].
PHST001 induces macrophage-mediated phagocytosis of human breast (BT474, SKBR3, MFM223), colorectal (HT29, DLD1), ovarian (NCI-H292, NCI-H1563, OVCAR3, SKOV3), and pancreatic (BXPC3, PACADD-137) cancer cell lines[1].
PHST001 (5-100 μg/mL) does not induce release of IL6, TNFα, IL2, or IFNγ by human PBMCs[1].
PHST001 binds CD24 on SKOV3, OVCAR3, and primary mucinous, neuroendocrine, and serous ovarian carcinoma cells with a Kd of 31 nM to 117 nM, and binds >95% of EpCam+ cells from these primary subtypes[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PHST001 Related Antibodies
In Vivo

PHST001 (20 mg/kg; s.c.; 3 times per week; 18 doses) inhibits tumor growth and improving survival in an ovarian cancer PDX model in NSG mice[3].
PHST001 inhibits the formation of axillary lymph node metastases reduces the number and size of metastatic lesions in orthotopic xenograft models of human Her2+ breast cancer in NSG mice[2].
PHST001 significantly reduces the number and size of metastatic lesions in a disseminated intracardiac xenograft model of human Her2+ breast cancer in NSG mice[2].
PHST001 significantly reduces the number and size of metastatic lesions in a disseminated intracardiac syngeneic model of BT474 in nsg mice[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: NSG immunocompromised mice[3]
Dosage: 20 mg/kg
Administration: s.c.; 3 times per week; 18 doses
Result: Significantly inhibited growth of OVCAR3 ovarian cancer cell lines.
Significantly improved survival in treated mice.\n
Significantly inhibited growth of SKOV3 ovarian cancer cell lines.
Significantly improved survival in treated mice.\nEnhanced chemotherapy efficacy.
Significantly inhibited tumor growth.
Enhanced survival in treated mice.
Gene ID
Accession

P25063-1
Target

CD24
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

PHST001 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

PHST001PHST 001PHST-001Transmembrane GlycoproteinSiglec10primary ovarian tumor cellsFc receptorsmacrophagesbreast cancertriple negative breast cancerCD24ovarian cancer cellsHer2+ breast cancerovarian cancerInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
PHST001
Cat. No.:
HY-P992441
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.